A KEEN FOCUS ON INNOVATION fueled by an extraordinary legacy of healthcare advances
By broadening our innovation focus, we will continue to deliver clinically relevant and economically valuable solutions that meet our customers’ needs in the most efficient and effective manner.
Covidien has a long history of innovation, having pioneered products in surgical stapling, wound care, pulse oximetry, laparoscopic instrumentation, electrosurgery, vessel sealing and contrast media delivery.
We continue to provide clinical value and product leadership by collaborating with physicians to create new products and improve on older technology. To learn more about just a few of our innovative products, follow the links at left.
Covidien is committed to research and development (R&D), dedicating more than $600 million to R&D in 2012 alone. With a global R&D footprint that includes facilities in Asia, Europe and the United States, we are dedicated to developing products that meet the needs of our diverse markets. If you have a product idea, please submit it at Your Ideas at Covidien.
IMPROVING PATIENT OUTCOMES while focused on patient safety
At Covidien, we take very seriously our responsibility to provide high-quality products as safely as possible. Innovations in patient health and safety go beyond the products, though. We have launched patient-focused initiatives designed to benefit countless individuals. These efforts target a prominent disease, a chronic condition and a safety concern, all of which affect millions of people today.
Bariatric Patients - More than one-third of U.S. adults were classified as obese in 2007-2008.1 Obesity can lead to many health concerns, such as type 2 diabetes, sleep apnea and heart disease. Covidien is leading the way in providing tools and resources for patients and clinicians relating to surgical options that may help patients control or resolve their type 2 diabetes.
www.bariatrics4diabetes.com (patient-focused site)
www.covidien.com/bariatricspro (clinician-focused site)
People With Pain – More than one-quarter of Americans over the age of 20, or 76.2 million people, report they have had a problem with pain2, along with many others worldwide. As a leading supplier of opioid analgesics, Covidien embraces its responsibility to ensure responsible prescribing, dispensing, use and storage of these analgesics to avoid misuse, abuse, addiction, diversion and overdose.
The Collaborating and Acting Responsibly to Ensure Safety (C.A.R.E.S.) AllianceSM is a growing coalition of healthcare provider, patient advocacy, law enforcement and drug diversion investigator organizations and individuals. The mission: improve pain management outcomes for people with pain and for society through education that is both innovative and science-based.
Safe Injection Practices – Covidien was a founding member of the Safe Injection Practices Coalition (SIPC), along with healthcare practitioner organizations, hospital groups and other manufacturers. Together with the U.S. Centers for Disease Control and Prevention, the SIPC launched the One & Only Campaign, a public health initiative designed to raise awareness among patients and healthcare providers about safe injection practices. The campaign aims to eradicate outbreaks resulting from unsafe injection practices.
- American Academy of Pain Medicine. “Facts and Figures on Pain.” Page last accessed August 2010. http://www.painmed.org/patient/facts.html